LLY ▲ +1.3% - Eli Lilly and Company $LLY - New composite outcomes data show patients treated with Lilly's Omvoh (mirikizumab-mrkz) achieved comprehensive corticosteroid-free disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease at one year 15-OCT-2026 08:03 AM ET